Hyperfine price target lowered to $1.20 from $1.50 at B. Riley

B. Riley analyst Yuan Zhi lowered the firm’s price target on Hyperfine (HYPR) to $1.20 from $1.50 and keeps a Buy rating on the shares. The top-line miss in in Q4 was driven by extended timelines in legacy critical care business, and guidance for the first half of 2025 implies a continued slowdown, while 2025 guidance implies a sharp revenue increase in the second half of the year, the analyst tells investors in a research note. Uncertainty remains, and management will have more visibility in the coming months amid new sales reps and new opportunities, the firm adds.